[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.Read more
Arnaud François, Pascal Grondin, Guillaume Das Dores, Aurore Sors, Anne-Pascale Luzy, Cédric Vinson, Yann Lamotte, Petra Blom, Arnaud Le Tiran, Laurence Danober, Johannes Krupp, Jan Hoflack and Nicolas Ancellin
Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are the most common genetic cause of Parkinson’s disease, leading to the development of LRRK2 inhibitors as potential therapeutic approach. Among them, Compound A has recently been selected as a potent, selective and brain-penetrant LRRK2 inhibitor. In order to confirm its in vivo target engagement and equipotency on wild type and G2019S LRRK2 mutants, several Pharmacokinetic/Pharmacodynamic (PK/PD) studies were performed in rodent and non-rodent species.
Prepared in collaboration with Servier
Please see the accompanying poster for the In vitro pharmacological profile of compound A